Medium- to Long-Term Impact of Rotavirus Vaccination on Hospital Care in Belgium: A 7-Year Follow-Up of the Rotavirus Belgium Impact Study (RotaBIS)

Baudouin Standaert, Danielle Strens, Ali Alwan, Marc Raes, Baudouin Standaert, Danielle Strens, Ali Alwan, Marc Raes

Abstract

Introduction: Rotavirus (RV) vaccination was introduced in Belgium in 2006. With the high uptake it had (>85%), a sharp decline in hospitalizations was observed during the first years after vaccine introduction. The objective of this study was to investigate whether this decline was maintained and to simulate projections.

Methods: The Rotavirus Belgium Impact Study allowed an analysis of the RV vaccine impact amongst children in 11 hospitals in Belgium over a 9-year period (2005-2013) with 2 years pre- and 7 years post-vaccine introduction. Results were compared by year and by subsequent birth cohort aging up to 5 years. The two different analysis methods helped dismantling the different (direct and indirect) effects of vaccine protection to simulate future hospitalization trends.

Results: During the whole observation period, 40,552 RV detection tests were performed of which 5832 were positive (14.4%). After RV vaccine introduction, a significant reduction in number of tests performed (-38%) was combined with a dramatic drop in numbers of positive tests (-76.6%). The decreases were spectacular during the first two years of vaccine introduction; after that period, the decrease flattened. Cross-sectional comparison with cohort data showed that the initial drop was heavily influenced by the herd effect of the vaccine. Cohort analysis demonstrated a low rate of residual disease over time, suggesting another infection source other than the child population.

Conclusion: The residual disease will be maintained in the community when a same vaccination strategy is continued over time, starting vaccination of children only at 6 weeks' time.

Funding: GlaxoSmithKline Biologicals SA.

Trial registration: ClinicalTrials.gov identifier, NCT01563146.

Keywords: Children; Gastroenteritis; Hospitalization; Rotavirus; Vaccination.

Figures

Fig. 1
Fig. 1
Number of RV-negative and RV-positive tests performed per year in the 11 participating centers Nbr number, RV rotavirus
Fig. 2
Fig. 2
Distribution of RV-positive tests by age-group and year. Nbr number, RV rotavirus, mo months, yrs years
Fig. 3
Fig. 3
Comparing observed data (a) with simulations of adding residual disease over time (b); with fixed reduction in RV-positive tests without residual disease (c); vaccine waning (−10% per year) (d); changing vaccine coverage rate (85% to 65%) (e). Nbr number, RV rotavirus
Fig. 4
Fig. 4
Difference in proportion of RV-positive tests during the post-vaccination period (2012 and 2013) compared with the pre-vaccination period (2006) in each hospital center (code). RV rotavirus

References

    1. Karsten C, Baumgarte S, Friedrich AW, et al. Incidence and risk factors for community-acquired acute gastroenteritis in north-west Germany in 2004. Eur J Clin Microbiol Infect Dis. 2009;28(8):935–943. doi: 10.1007/s10096-009-0729-1.
    1. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12(2):304–306. doi: 10.3201/eid1202.050006.
    1. Iturriza-Gomara M, Dallman T, Banyai K, et al. Rotavirus surveillance in Europe, 2005–2008: web-enabled reporting and real-time analysis of genotyping and epidemiological data. J Infect Dis. 2009;200(Suppl 1):S215–S221. doi: 10.1086/605049.
    1. Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics. 2009;123(3):e393–e400. doi: 10.1542/peds.2008-2088.
    1. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study. J Infect Dis. 2007;195(Suppl 1):S4–S16. doi: 10.1086/516714.
    1. Giaquinto C, Van Damme P, Huet F, et al. Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL Study. J Infect Dis. 2007;195(Supplement 1):S26–S35. doi: 10.1086/516717.
    1. Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine. 1999;17(18):2207–2222. doi: 10.1016/S0264-410X(98)00376-4.
    1. Huilan S, Zhen LG, Mathan MM, et al. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull World Health Organ. 1991;69(5):549–555.
    1. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996;335(14):1022–1028. doi: 10.1056/NEJM199610033351404.
    1. Diez-Domingo J, Martin IO, Sanz AB, et al. Rotavirus gastroenteritis among children under five years of age in Valencia, Spain. Pediatr Infect Dis J. 2006;25(5):455–457. doi: 10.1097/01.inf.0000217378.30444.21.
    1. Bilcke J, Beutels P, De Smet F et al. KCE reports 54B: Vaccination des nourrissons contre le rotavirus en Belgique—Analyse coût-efficacité. Bruxelles: Centre fédéral d’expertise des soins de santé (KCE); 2007. Report No.: KCE reports 54B, Dépot légal D2007/10.273/10.
    1. Bilcke J, Van DP, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and “no medical care’’ disease impact in Belgium. Med Decis Making. 2009;29(1):33–50. doi: 10.1177/0272989X08324955.
    1. Velazquez FR. Protective effects of natural rotavirus infection. Pediatr Infect Dis J. 2009;28(3 Suppl):S54–S56. doi: 10.1097/INF.0b013e3181967c03.
    1. Anderson EJ. Prevention and treatment of viral diarrhea in pediatrics. Expert Rev Anti Infect Ther. 2010;8(2):205–217. doi: 10.1586/eri.10.1.
    1. Chandran A, Fitzwater S, Zhen A, Santosham M. Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines. Biologics. 2010;4:213–229.
    1. Vesikari T, Van Damme P, Giaquinto C, et al. European society for paediatric infectious diseases/European society for paediatric gastroenterology, hepatology, and nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. J Pediatr Gastroenterol Nutr. 2008;46(5):615–618. doi: 10.1097/MPG.0b013e31816e213a.
    1. Rotavirus vaccines WHO position paper: January 2013—Recommendations. Vaccine. 2013;31(52):6170–1.
    1. World Health Organization Meeting of the immunization Strategic Advisory Group of Experts, April 2009—conclusions and recommendations. Wkly Epidemiol Rec. 2009;23(84):220–236.
    1. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis. 2006;6(12):805–812. doi: 10.1016/S1473-3099(06)70657-0.
    1. Parez N, Giaquinto C, Du RC, et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis. 2014;14(5):416–425. doi: 10.1016/S1473-3099(14)70035-0.
    1. Paulke-Korinek M, Kundi M, Rendi-Wagner P, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine. 2011;29(15):2791–2796. doi: 10.1016/j.vaccine.2011.01.104.
    1. Paulke-Korinek M, Kollaritsch H, Aberle SW, et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine. 2013;31(24):2686–2691. doi: 10.1016/j.vaccine.2013.04.001.
    1. Vesikari T, Sutherland D, Jackson AEM. Report of the ‘European Expert Meeting on Rotavirus Vaccination’, Tampere, Finland, 19–20 May 2009. Vaccine. 2009;27(52):7222–7227. doi: 10.1016/j.vaccine.2009.09.115.
    1. Hanquet G, Ducoffre G, Vergison A, et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine. 2011;29(29–30):4698–4703. doi: 10.1016/j.vaccine.2011.04.098.
    1. Raes M, Strens D, Vergison A, Verghote M, Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J. 2011;30(7):e120–e125. doi: 10.1097/INF.0b013e318214b811.
    1. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine. 2010;28(47):7507–7513. doi: 10.1016/j.vaccine.2010.09.004.
    1. Zlamy M, Kofler S, Orth D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis. 2013;13:112. doi: 10.1186/1471-2334-13-112.
    1. Vesikari T, Uhari M, Renko M, et al. Impact and effectiveness of RotaTeq(R) vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J. 2013;32(12):1365–1373. doi: 10.1097/INF.0000000000000086.
    1. Braeckman T, Theeten H, Lernout T et al. Rotavirus vaccination coverage and adherence to recommended age among infants in Flanders (Belgium) in 2012. Eurosurveillance. 2014;19(20) (pii=20806).
    1. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine. 2012;30(3):552–564. doi: 10.1016/j.vaccine.2011.11.064.
    1. Fleiss J, Levin B, Paik M. Statistic methods for rates and proportions. Probabilties and statistics. Hoboken:New Jersay Wiley Series edn. Wikey Series; 2003.
    1. Standaert B, Gomez JA, Raes M, et al. Impact of rotavirus vaccination on hospitalisations in belgium: comparing model predictions with observed data. PLoS One. 2013;8(1):e53864. doi: 10.1371/journal.pone.0053864.
    1. Owain J. Vaccine Knowledge Project. Available from: . Accessed 23 Dec 2014.
    1. Public Health England. Summary of Surveillance of norovirus and rotavirus vaccination. Available from: . Accessed 27 Nov 2014.
    1. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007;370(9601):1757–1763. doi: 10.1016/S0140-6736(07)61744-9.
    1. Standaert B, Demarteau N, Talbird S, Mauskopf J. Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine. 2010;28(Suppl 6):G30–G38. doi: 10.1016/j.vaccine.2010.06.015.
    1. Ethgen O, Standaert B. Population- versus cohort-based modelling approaches. Pharmacoeconomics. 2012;30(3):171–181. doi: 10.2165/11593050-000000000-00000.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa